The FDA has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback